title: Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
abstract: The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of several virus targets and key host cell factors involved in virus replication or mediating the inflammatory response. Virus targets included the influenza haemagglutinin, neuraminidase and M2 proteins, and both the respiratory syncytial virus and influenza polymerases and nucleoproteins. Therapies for rhinoviruses and MERS and SARS coronaviruses were also discussed. With the emerging development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. Topics covered all aspects from structural and molecular biology to preclinical and clinical studies. The importance of suitable clinical trial endpoints and regulatory issues were also discussed from the perspectives of both industry and government. This meeting summary provides an overview, not only for the conference participants, but also for those interested in the current status of antivirals for respiratory viruses.
authors.affiliation: CSIRO, 343 Royal Parade, Parkville, Australia. Electronic address: mck245@csiro.au.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: McKimm-Breschkin
authors.affiliation: Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: agf1@cdc.gov.
authors.forename: Alicia M
authors.initials: AM
authors.lastname: Fry
mesh_terms: D000547:Amantadine / Q000627:therapeutic use; D019067:Antibody-Dependent Enhancement; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018352:Coronavirus Infections / Q000188:drug therapy; D024882:Drug Resistance, Viral; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology; D009439:Neuraminidase / Q000627:therapeutic use; D009975:Orthomyxoviridae / Q000187:drug effects; D053139:Oseltamivir / Q000627:therapeutic use; D010850:Picornaviridae Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000821:virology*; D012299:Rimantadine / Q000627:therapeutic use; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy; D013781:Texas; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D012299:Rimantadine; D053139:Oseltamivir; D000547:Amantadine; D009439:Neuraminidase
keywords: Antiviral; Influenza; Isirv-AVG; Respiratory virus